Asceneuron
Asceneuron researches and develops oral small molecule therapeutics targeting tauopathies for treating progressive supranuclear palsy (PSP), other related neurodegenerative diseases and Alzheimer’s disease. The lead product, an O-GlcNAcase inhibitor that in preclinical studies has been demonstrated to modulate tau pathology, has entered the critical regulatory studies to allow its entry into human clinical testing. Neuronal deposits of the microtubule-associated tau protein are a common feature of tauopathies and known to be a major contributor to neurodegenerative diseases.
Sector
Biopharmaceuticals
Strategy
Capital
Status
Active
Website
www.asceneuron.com
Related News
Asceneuron expands scientific Advisory Board with world leading experts in neurodegenerative diseases
Industry veteran Abbas Hussain appointed as Chair of Asceneuron
Asceneuron welcomes Barbara Angehrn Pavik as new CEO as it gears up for next phase of growth
Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor from Asceneuron, exclusively to treat Progressive Supranuclear Palsy (PSP)
Asceneuron awarded second grant from The Michael J. Fox Foundation for accelerated research into novel Parkinson’s disease therapies
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.